sur NICOX (EPA:COX)
Nicox succeeds in its capital increase of 3.3 million euros
Nicox SA announced the success of its capital increase with maintenance of preferential subscription rights. This operation made it possible to raise 3.3 million euros, thanks to the issue of 13,154,900 new shares at a unit price of 0.25 euros per share, accompanied by share subscription warrants.
The company, specialized in ophthalmology and listed on Euronext Growth Paris, is thus extending its cash flow horizon until the end of February 2025. This will allow Nicox to continue the development of its main drug candidate, NCX 470, including the Phase study. 3 Denali.
Ocumension Therapeutics, a long-time partner, becomes the largest shareholder with 4.82% of the capital. Partnership discussions and evaluation of strategic options are also underway to secure the financial future.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NICOX